Similarly, in the study by Zhou et al. PD-L1 expression of ≥ 25% was found to improve PFS (hazard ratio = 0.37 [95% CI: 0.28 to 0.49], p < 0.0001) in those with lung cancer who were treated with tislelizumab [21]. The gene discussed is CD274; the disease is lung carcinoma.